Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative

Background and Objectives: The purposes of this study were to evaluate the tolerance, efficacy and safety of isovolemic erythrocytapheresis (EA) in nonanemic patients with hereditary hemochromatosis (HH), and to assess the usefulness of recombinant human erythropoietin (rHuEPO) associated with EA to...

Full description

Saved in:
Bibliographic Details
Published in:Vox sanguinis 2000-01, Vol.79 (1), p.40-45
Main Authors: Kohan, Abraham, Niborski, Ricardo, Daruich, Jorge, Rey, Jorge, Bastos, Fabiana, Amerise, Graciela, Herrera, Roberto, García, Marcelo, Olivera, Walter, Santarelli, María Teresa, Avalos, Julio Sánchez, Findor, Jorge
Format: Article
Language:English
Subjects:
Labile Blood Components and Blood Donation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objectives: The purposes of this study were to evaluate the tolerance, efficacy and safety of isovolemic erythrocytapheresis (EA) in nonanemic patients with hereditary hemochromatosis (HH), and to assess the usefulness of recombinant human erythropoietin (rHuEPO) associated with EA to reduce treatment duration. Materials and Methods: In 10 asymptomatic patients with serum ferritin >400 μg/l, transferrin saturation >50%, and GPT elevation, EA with rHuEPO and folic acid was performed. Results: Red cell indices, serum ferritin, and other iron metabolism parameters (serum iron, transferrin, and transferrin saturation); GPT and other laboratory data were considerably improved. Conclusion: This method offers better results in less time than traditional phlebotomy. EA with rHuEPO is an effective therapeutic alternative for patients with HH.
ISSN:0042-9007
1423-0410
DOI:10.1159/000031204